ANI PHARMACEUTICALS INC (ANIP) is a publicly traded company in the Unknown sector. Across all available filings, 29 corporate insiders have executed 681 transactions totaling $239.6M, demonstrating a bearish sentiment with -$234.1M in net insider flow. The most recent transaction on Feb 20, 2026 involved a sale of 1,730 shares valued at $134.9K.
No significant insider buying has been recorded for ANIP in the recent period.
No significant insider selling has been recorded for ANIP in the recent period.
Based on recent SEC filings, insider sentiment for ANIP is bearish with an Insider Alignment Score of 1/100 and a net flow of -$234.1M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at ANI PHARMACEUTICALS INC (ANIP) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 29 insiders are actively trading ANIP stock, having executed 681 transactions in the past 90 days. The most active insider is Muthusamy Shanmugam (Executive), who has made 75 transactions totaling $63.5M.
Get notified when executives and directors at ANIP file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 20, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | Sale | 1,730 | $77.99 | $134.9K | |
| Feb 20, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Sale | 5,323 | $78.02 | $415.3K | |
| Feb 19, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | Sale | 2,084 | $77.53 | $161.6K | |
| Jan 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sale | 500 | $84.33 | $42.2K | |
| Dec 18, 2025 | Davis Krista | Executive | Sale | 1,622 | $82.40 | $133.7K | |
| Dec 12, 2025 | Cook Meredith | Executive | Sale | 400 | $82.32 | $32.9K | |
| Dec 5, 2025 | P. Tannenbaum Renee | Executive | Sale | 1,800 | $81.15 | $146.1K | |
| Nov 13, 2025 | Cook Meredith | Executive | Sale | 400 | $87.27 | $34.9K | |
| Nov 13, 2025 | Gassert Chad | Executive | Sale | 94 | $88.00 | $8.3K | |
| Nov 13, 2025 | D. Walsh Patrick | Executive | Sale | 8,643 | $86.88 | $750.9K | Large |
| Nov 13, 2025 | D. Walsh Patrick | Executive | Gift | 3,000 | $N/A | $0 | |
| Nov 12, 2025 | Gassert Chad | Executive | Sale | 14,642 | $89.07 | $1.3M | Large |
| Oct 13, 2025 | Cook Meredith | Executive | Sale | 400 | $90.09 | $36.0K | |
| Sep 19, 2025 | Davis Krista | Executive | Sale | 1,000 | $98.04 | $98.0K | |
| Sep 12, 2025 | Cook Meredith | Executive | Sale | 400 | $98.42 | $39.4K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 234 | $236.9M | 89.6% |
Payment(F) | 174 | $17.2M | 6.5% |
Exercise(M) | 39 | $7.5M | 2.8% |
Purchase(P) | 25 | $2.7M | 1.0% |
Gift(G) | 7 | $0 | 0.0% |
Award(A) | 202 | $0 | 0.0% |
Insider selling pressure at ANI PHARMACEUTICALS INC has increased, with 29 insiders executing 681 transactions across all time. Total sales of $236.9M significantly outpace purchases of $2.7M, resulting in a net outflow of $234.1M. This selling activity appears largely discretionary, which may warrant closer attention from investors.